A Study on the Anti-Wrinkle Efficacy Assessment and Safety Evaluation of the Cluster of Autologous Dermal Fibroblast on Bilateral Crow's Feet

NCT04818203

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	S.Biomedics Co., Ltd.
Enrollment	80 participants

Key Eligibility Criteria

Inclusion (11)

- Participants of ages 19 and older
- Those with at least 3 points (Moderate) of the IGA-LCL severity scale on both sides in the rest state during screening
- Those who have visually symmetrical periorbital wrinkles on both sides and have the same IGA-LCL severity scale score in the rest state
- Those who agreed to discontinue all dermatological treatments including facial wrinkle improvement during this study period
- Subjects with healthy and undamaged skin at the sampling area (e.g., behind the ears, inside of the arms, armpits, groin, etc.)

... and 6 more (see full listing online)

Exclusion (23)

- Those with arterial bleeding or severe variceal bleeding in the body
- Those with hypersensitivity to bovine protein or gentamicin
- Pregnant and breast-feeding or who planning to conceive within six months of clinical trial medication
- Out of who are pregnant or breast-feeding and A woman who is likely to be pregnant in a postmenopausal or a state of non-Infertility surgery and men with reproductive abilities not willing or planning to use the appropriate contraception defined in this clinical trial during their participation in clinical trials
- Those with or suspected of having autoimmune diseases (e.g., myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, etc.)

... and 18 more (see full listing online)

Locations (1 total)

Chung-Ang University Hospital, Seoul, South Korea